Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Shigella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Shigella species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).

Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Salmonella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Salmonella species in various settings (e.g., food safety, sanitation, probiotics).

Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Listeria species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Listeria species in various settings (e.g., food safety, sanitation, probiotics).

Abstract: The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Salmonella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Salmonella species in various settings (e.g., food safety, sanitation, probiotics).

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract: The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.

Abstract: Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens-specific bacteriophage, wherein each bacteriophage has lytic activity against at least five C. perfringens strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens-specific bacteriophage.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.

Abstract: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Salmonella.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli in various settings.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Clostridium perfringens, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Clostridium perfringens in various settings.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Clostridium perfringens, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Clostridium perfringens in various settings.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Pseudomonas aeruginosa, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Pseudomonas aeruginosa in various settings.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli in various settings.

Abstract: The present invention is directed to isolated bacteriophage having strong lytic activity against strains of E. coli O157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of E. coli O157:H7 in various settings.

Abstract: The present invention is directed to isolated Listeria monocytogenes bacteriophage, and methods of using Listeria monocytogenes bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Listeria monocytogenes. The present invention also contemplates the use of Listeria monocytogenes bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Listeria monocytogenes.